ProQR Therapeutics is a clinical stage biopharmaceutical company. Co. is developing a pipeline of RNA therapies for inherited retinal diseases. Beyond its clinical portfolio, Co. has discovered and developed two proprietary RNA editing platform technologies, Axiomer and TRIDENT. Co.'s editing oligonucleotides are designed to recruit endogenous Adenosine Deaminases Acting on RNA, enzymes to make single nucleotide changes in the RNA in a manner at a desired location. TRIDENT is Co.'s RNA pseudouridylation platform that enables the selective suppression of nonsense mutations that cause human genetic disease. The PRQR stock yearly return is shown above.
The yearly return on the PRQR stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the PRQR annual return calculation with any dividends reinvested as applicable (on ex-dates).
|